Sttr phase i: accelerating molecular dynamics using coarse-grained neural network potentials

Giwotech Inc. received a $305,000 Phase I Small Business Technology Transfer (STTR) Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) on July 15, 2025, with a completion date of June 30, 2026. The company, based in Dorchester, Massachusetts, is developing a neural network-based molecular dynamics simulation platform designed to accelerate drug discovery processes. The core product leverages advanced artificial intelligence (AI) and coarse-grained neural network potentials to enable protein system simulations up to 500 times faster than conventional graphics processing unit (GPU)-based classical molecular dynamics simulators while maintaining accuracy and stability.

The technology addresses current limitations in molecular dynamics simulations, including insufficient sampling, model inaccuracies, and complex data interpretation challenges. By enhancing simulation speed and accuracy, the platform is intended to enable pharmaceutical companies to screen drug candidates more rapidly, improve predictions of drug efficacy and side effects, and potentially increase clinical trial success rates by 20-30%. The commercial applications target the pharmaceutical industry, particularly companies focused on rare diseases and personalized medicine, with projected annual revenues of $2–5 million by year three of production and potential cost savings of $300 million to $1 billion per approved drug through reduced development timelines.

Abstract

The broader impact/commercial potential of this small business technology transfer (sttr) phase i project is to revolutionize drug discovery by accelerating molecular dynamics simulations through advanced AI techniques. This project aims to reduce drug development timelines by 2-5 years and cut costs by $300 million to $1 billion per approved drug. By enhancing the speed and accuracy of simulations, this technology will enable faster screening of potential drug candidates, improving the prediction of drug efficacy and side effects, and potentially increasing clinical trial success rates by 20-30%. The innovation will enhance scientific understanding by revealing previously unknown protein conformations and binding sites, potentially leading to breakthroughs in personalized medicine and treatments for rare diseases. The market opportunity lies in the pharmaceutical industry, where the technology can provide a competitive advantage by significantly reducing the time and cost of drug development. The business model involves service to pharmaceutical companies, with potential annual revenues projected to reach $2-5 million by year three of production, targeting the initial market segment of pharmaceutical companies focused on rare diseases and personalized medicine. This small business technology transfer (sttr) phase i project addresses the limitations of current molecular dynamics simulations, including insufficient sampling, model inaccuracies, and complex data interpretation. The research objectives of this project are to develop a robust neural network model capable of simulating protein systems up to 500 times faster than current graphics processing unit-based classical molecular dynamic simulators while maintaining accuracy and stability. The proposed research combines four key advancements: enhanced coarse-grained mapping to reduce inherent noise in atomic forces, advanced energy matching techniques for estimating absolute free energies, active learning for continuous model refinement, and hessian matching for improved interpolation and extrapolation capabilities. The project involves rigorous mathematical derivations, extensive data generation, and iterative model improvements to overcome technical challenges including hidden entropy contributions and the need for comprehensive training datasets. The anticipated technical results include a platform that significantly accelerates drug discovery processes, enabling the exploration of rare molecular events and complex biological systems. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.- subawards are planned for this award.